Artificial Intelligence
for Reproductive Medicine

Our mission is to harness the power of AI to improve fertility care and IVF outcomes, lower its costs, and alleviate emotional stress of the patient journey.

We are an innovation-focused fertility technology company developing non-invasive AI-enabled fertility solutions to improve clinical decision making in fertility care and in vitro fertilization (IVF).

Currently there is no standardized visual assessment tool used by embryologists to evaluate the reproductive potential of a mature human egg; the most step-limiting variable in a successful pregnancy.

Future Fertility’s first non-invasive AI solution can detect features of a woman’s egg that are invisible to the human eye and can predict the likelihood of fertilization and embryo (blastocyst) development. The product is already used in a number of innovative clinics around the world and has been consistently shown to be significantly more accurate at predicting egg quality compared to current methods.

Products

VIOLET - Oocyte Prediction

Non-invasive assessment to predict egg outcomes for social egg freezing patients

In Selected Clinics

MAGENTA - Oocyte Scoring

Non-invasive assessment of egg quality for patients going through IVF cycle

Coming Soon

Upcoming

Additional non-invasive assessment products to improve IVF journey

For Clinicians

Future Fertility is developing first-in-class non-invasive software solutions to help clinicians and embryologists to personalize care and as a result improve fertility care outcomes.

Future Fertility’s first non-invasive AI solution can detect features of a woman’s egg that are invisible to the human eye and can predict the likelihood of fertilization and embryo (blastocyst) development. The product is already used in a number of innovative clinics around the world and has been consistently shown to be significantly more accurate at predicting egg quality compared to current methods.

For Patients

Currently there is no standardized visual assessment tool used by embryologists to evaluate the reproductive potential of a mature human egg and provide insight into the egg’s quality before freezing or IVF. It might be surprising, but other than a woman’s age (and general health), there is no strong predictor of egg quality.

Future Fertility is therefore proud to offer Violet™, the first AI-powered egg assessment tool that will help patients gain insight into the quality of the eggs they are freezing. Our software solution can detect patterns in oocytes that the human eye cannot see, and has been consistently shown to be significantly more accurate at predicting egg quality compared to current methods.

With our tool, doctors are now able to provide a report with photos of your eggs, allowing for a more in-depth discussion about the quality of the eggs you are freezing. The report will give patients the opportunity to make more informed decisions regarding your fertility journey, for example whether an additional cycle is required to produce additional eggs for freezing.

For Egg Freezing Patients

About Us

The company’s mission is to harness the power of AI to improve fertility care and IVF outcomes, lower its costs, and alleviate emotional stress of the patient journey.

IVF is expensive and is fraught with low success rates, with only ~30% of egg retrievals across all age groups resulting in live births.

We have developed the first Artificial Intelligence image analysis tool to non-invasively evaluate oocytes (eggs), creating the only objective classification and prediction tool Violet™ for an oocyte.

Beyond our flagship egg prediction software product Violet™ developed for patients undergoing oocyte cryopreservation, Future Fertility has additional AI solutions in its pipeline, unlocking key decision points in the 2.5 million IVF cycles per year, for which no non-invasive tools exist to date.

BSc, MSc, MD, FRCSC
CMO and Co-Founder
CTO and Co-Founder
B.Sc, M.Sc, ELD, PhD
Head of Embryology
Board Member and Co-Founder
Board Member
Whitecap Venture Partners
Board Member

Board of Advisors

Associate Professor, Reproductive Endocrinology and Infertility UCSF

CEO and Chief Medical Officer of Vios Fertility Institute

CEO of Genea Biomedx

Request More Information